Dosimetric Quantities in Neuroendocrine Tumors over Treatment Cycles with ¹⁷⁷Lu-DOTATATE.

ABSTRACT: Tumor dosimetry was performed for ¹⁷⁷Lu-DOTATATE with the aims of better understanding the range and variation of the tumor-absorbed doses (ADs), how different dosimetric quantities evolve over the treatment cycles, and whether this evolution differs depending on the tumor grade. Such information is important for radiobiologic interpretation and may inform the design of alternative administration schemes. Methods: The data came from 41 patients with neuroendocrine tumors (NETs) of grade 1 (n = 23) or 2 (n = 18) who had received between 2 and 9 treatment cycles. Dosimetry was performed for 182 individual lesions, giving a total of 880 individual AD assessments across all cycles. Hybrid planar-SPECT/CT imaging was used, including quantitative SPECT reconstruct

SUBMITTER: Roth D 

PROVIDER: S-EPMC8978188 | biostudies-literature | 2022 Mar

REPOSITORIES: biostudies-literature